Summary of Study ST000524

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000387. The data can be accessed directly via it's Project DOI: 10.21228/M81G7P This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)
Study IDST000524
Study TitleEffects of Curcumin Supplementation on the Amino Acid Concentration of Older Adults: Relation to Vascular Function (part 1)
Study SummaryPerform amino acid concentrations metabolite analysis related to nitric oxide biology, oxidative stress and inflammation in plasma before and after 12 weeks of oral curcumin (2000 mg/d) or placebo (double-blind, randomized) in men and women aged 45-79 years who are free from clinical cardiovascular disease.
Institute
Mayo Clinic
Last NameSeals
First NameDouglas
AddressDepartment of Integrative Physiology University of Colorado Boulder, CO 80309
Emailseals@colorado.edu
Phone303-492-5305
Submit Date2016-12-14
Analysis Type DetailLC-MS
Release Date2018-12-11
Release Version1
Douglas Seals Douglas Seals
https://dx.doi.org/10.21228/M81G7P
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR000387
Project DOI:doi: 10.21228/M81G7P
Project Title:Mayo Metabolomics Pilot and Feasibility Award: Effects of Curcumin Supplementation on the Plasma Metabolome of Older Adults: Relation to Vascular Function
Project Summary:Age is the major risk factor for cardiovascular diseases (CVD). Two key contributors to the increased risk of CVD in middle-aged and older (MA/O) adults are stiffening of the large elastic arteries and the development of vascular endothelial dysfunction, indicated by impaired nitric oxide (NO)-induced endothelium-dependent dilation (EDD). The mechanisms by which aging causes arterial dysfunction are incompletely understood, but involve reductions in NO bioavailability associated with the development of oxidative stress and inflammation. Thus, establishing novel strategies to reduce arterial stiffness and increase vascular endothelial function in MA/O adults by increasing NO bioavailability and reducing oxidative stress and inflammation are a high biomedical research priority. Curcumin is a naturally occurring phenol found in the Indian spice turmeric that improves physiological function in animal models of age-related diseases and is a promising nutraceutical for intervention for promoting healthy aging. Our preclinical results indicate that chow supplemented with curcumin reduces aortic pulse wave velocity (PWV), the most common and clinically important measure of large elastic artery stiffness, restores NO-mediated EDD and reduces arterial oxidative stress and inflammation in old C57/BL6 mice. Preliminary data from our recently funded NIH R21 pilot grant indicate that curcumin supplementation improves vascular function in humans. It is possible that changes in the circulating (plasma) metabolome with oral curcumin supplementation will provide insight into novel metabolic mechanisms by which curcumin may improve vascular function. The goal of this project is to identify key metabolic pathways that change with oral curcumin supplementation and to relate those changes with improvements in vascular function in MA/O adults with initial endothelial dysfunction. Metabolomic analysis of plasma samples at baseline also may produce unique molecular signatures that predict responsiveness (changes in vascular function) to curcumin supplementation among individuals.
Institute:Mayo Clinic
Last Name:Seals
First Name:Douglas
Address:Department of Integrative Physiology University of Colorado Boulder, CO 80309
Email:seals@colorado.edu
Phone:303-492-5305

Subject:

Subject ID:SU000546
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Species Group:Human

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id group Time point
SA027463ms5535-29Old-Curcumin Post
SA027464ms5590-15Old-Curcumin Post
SA027465ms5590-22Old-Curcumin Post
SA027466ms5535-15Old-Curcumin Post
SA027467ms5535-18Old-Curcumin Post
SA027468ms5535-27Old-Curcumin Post
SA027469ms5535-20Old-Curcumin Post
SA027470ms5535-22Old-Curcumin Post
SA027471ms5590-27Old-Curcumin Post
SA027472ms5590-29Old-Curcumin Post
SA027473ms5535-3Old-Curcumin Post
SA027474ms5590-3Old-Curcumin Post
SA027475ms5590-25Old-Curcumin Post
SA027476ms5590-5Old-Curcumin Post
SA027477ms5535-10Old-Curcumin Post
SA027478ms5535-8Old-Curcumin Post
SA027479ms5535-26Old-Curcumin Pre
SA027480ms5590-14Old-Curcumin Pre
SA027481ms5590-4Old-Curcumin Pre
SA027482ms5535-28Old-Curcumin Pre
SA027483ms5535-19Old-Curcumin Pre
SA027484ms5535-9Old-Curcumin Pre
SA027485ms5590-24Old-Curcumin Pre
SA027486ms5535-7Old-Curcumin Pre
SA027487ms5590-26Old-Curcumin Pre
SA027488ms5535-2Old-Curcumin Pre
SA027489ms5535-14Old-Curcumin Pre
SA027490ms5590-28Old-Curcumin Pre
SA027491ms5535-21Old-Curcumin Pre
SA027492ms5590-2Old-Curcumin Pre
SA027493ms5535-17Old-Curcumin Pre
SA027494ms5590-21Old-Curcumin Pre
SA027495ms5590-18Old-Placebo Post
SA027496ms5590-10Old-Placebo Post
SA027497ms5590-13Old-Placebo Post
SA027498ms5590-20Old-Placebo Post
SA027499ms5590-8Old-Placebo Post
SA027500ms5535-32Old-Placebo Post
SA027501ms5535-34Old-Placebo Post
SA027502ms5590-32Old-Placebo Post
SA027503ms5590-34Old-Placebo Post
SA027504ms5535-25Old-Placebo Post
SA027505ms5535-13Old-Placebo Post
SA027506ms5590-36Old-Placebo Post
SA027507ms5535-5Old-Placebo Post
SA027508ms5535-36Old-Placebo Post
SA027509ms5535-4Old-Placebo Pre
SA027510ms5535-24Old-Placebo Pre
SA027511ms5590-19Old-Placebo Pre
SA027512ms5535-12Old-Placebo Pre
SA027513ms5590-35Old-Placebo Pre
SA027514ms5590-17Old-Placebo Pre
SA027515ms5535-31Old-Placebo Pre
SA027516ms5590-7Old-Placebo Pre
SA027517ms5590-31Old-Placebo Pre
SA027518ms5590-33Old-Placebo Pre
SA027519ms5535-33Old-Placebo Pre
SA027520ms5535-35Old-Placebo Pre
SA027521ms5590-9Old-Placebo Pre
SA027522ms5590-12Old-Placebo Pre
SA027523ms5590-37young Baseline
SA027524ms5590-30young Baseline
SA027525ms5590-1young Baseline
SA027526ms5535-23young Baseline
SA027527ms5535-16young Baseline
SA027528ms5535-11young Baseline
SA027529ms5535-6young Baseline
SA027530ms5535-30young Baseline
SA027531ms5535-37young Baseline
SA027532ms5590-16young Baseline
SA027533ms5590-11young Baseline
SA027534ms5590-6young Baseline
SA027535ms5535-1young Baseline
SA027536ms5590-23young Baseline
Showing results 1 to 74 of 74

Collection:

Collection ID:CO000540
Collection Summary:Healthy men & women aged 45-79 without clinical CVD, but with below normal baseline endothelial dysfunction (FMDBA < 7%).
Sample Type:Blood

Treatment:

Treatment ID:TR000560
Treatment Summary:A 12-week randomized, double-blind, placebo controlled study will be conducted. After CTRC screening for inclusion/exclusion criteria, qualified subjects will be randomly assigned to 1 of 2 groups. The investigators involved in the acquisition and analysis of key outcomes will be blinded to the curcumin intake status of the subjects. With the assistance of dietary monitoring from the UC-Boulder CTRC bionutritionists, subjects will maintain their baseline diet with either unchanged (control) or enhanced curcumin intake delivered as capsules (Longvida®, Verdure Sciences): Group 1 = placebo (inert substances); Group 2 = curcumin (2000mg curcumin/day). Extensive published work has established that the curcumin dose of 2000 mg/day is well tolerated and safe. Sessions 1 & 2: Screening measurements. Session 3: Baseline measurements and blood draw. Sessions 4-8 (every other week to assess adherence and overall subject well-being): Body weight, BP, adherence, discuss any problems. Session 9: Identical to session 3 (stop intake of capsules after completion of post-testing).

Sample Preparation:

Sampleprep ID:SP000553
Sampleprep Summary:Venous blood sampling. All blood samples are handled in a similar time frame and immediately spun to extract plasma and stored in our -80 freezer until ready for analysis. Amino Acid concentrations were measured.

Combined analysis:

Analysis ID AN000802
Analysis type MS
Chromatography type Reversed phase
Chromatography system Waters Acquity
Column Waters Acquity BEH C18 (150 x 2.1mm,1.7um)
MS Type ESI
MS instrument type Triple quadrupole
MS instrument name Thermo Quantum Ultra
Ion Mode POSITIVE
Units uM

Chromatography:

Chromatography ID:CH000577
Instrument Name:Waters Acquity
Column Name:Waters Acquity BEH C18 (150 x 2.1mm,1.7um)
Chromatography Type:Reversed phase

MS:

MS ID:MS000709
Analysis ID:AN000802
Instrument Name:Thermo Quantum Ultra
Instrument Type:Triple quadrupole
MS Type:ESI
Ion Mode:POSITIVE
  logo